BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 35076701)

  • 1. Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020.
    Desai A; Scheckel C; Jensen CJ; Orme J; Williams C; Shah N; Leventakos K; Adjei AA
    JAMA Netw Open; 2022 Jan; 5(1):e2144923. PubMed ID: 35076701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Retail Prices of Prescription Dermatologic Drugs From 2009 to 2015.
    Rosenberg ME; Rosenberg SP
    JAMA Dermatol; 2016 Feb; 152(2):158-63. PubMed ID: 26606197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
    Wineinger NE; Zhang Y; Topol EJ
    JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Competition and price among brand-name drugs in the same class: A systematic review of the evidence.
    Sarpatwari A; DiBello J; Zakarian M; Najafzadeh M; Kesselheim AS
    PLoS Med; 2019 Jul; 16(7):e1002872. PubMed ID: 31361747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019.
    Clemans-Cope L; Epstein M; Banthin J; Kesselheim AS; Hwang TJ
    JAMA Health Forum; 2023 Jan; 4(1):e225012. PubMed ID: 36637815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in Drug List Prices and Amounts Paid by Patients and Insurers.
    Yang EJ; Galan E; Thombley R; Lin A; Seo J; Tseng CW; Resneck JS; Bach PB; Dudley RA
    JAMA Netw Open; 2020 Dec; 3(12):e2028510. PubMed ID: 33295971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
    Li DG; Joyce C; Mostaghimi A
    JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.
    Rome BN; Feldman WB; Desai RJ; Kesselheim AS
    JAMA Netw Open; 2021 May; 4(5):e218816. PubMed ID: 33944925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in manufacturer prices of brand name prescription drugs used by older Americans--first quarter 2004 update.
    Gross DJ; Schondelmeyer SW; Raetzman SO
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2004 Jun; (IB69):1-12, 1-2. PubMed ID: 15368653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases.
    Dickson S
    JAMA Netw Open; 2020 Sep; 3(9):e2016388. PubMed ID: 32915237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specialty Drug Price Trends in the Federal 340B Drug Discount Program.
    Lee CH; Chang J; McCombs J
    J Manag Care Spec Pharm; 2019 Feb; 25(2):178-187. PubMed ID: 30698090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
    Hong SH; Shepherd MD; Scoones D; Wan TT
    J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreasing utilization and increasing prices of brand-name oral contraceptive pills: Implications to societal costs and market competition.
    Zhang JX
    PLoS One; 2020; 15(6):e0234463. PubMed ID: 32525965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers' Compensation System.
    Wilson L; Turkistani F; Tran DM; Huang W; Lin TK
    Appl Health Econ Health Policy; 2019 Apr; 17(2):231-242. PubMed ID: 30484140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Price Index Methods and Drug Price Inflation Estimates for Hepatitis C Virus Medications.
    Mattingly TJ; Anderson GF; Levy JF
    JAMA Health Forum; 2023 Jun; 4(6):e231317. PubMed ID: 37294584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
    Raimond VC; Feldman WB; Rome BN; Kesselheim AS
    Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generic script share and the price of brand-name drugs: the role of consumer choice.
    Rizzo JA; Zeckhauser R
    Int J Health Care Finance Econ; 2009 Sep; 9(3):291-316. PubMed ID: 19130220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.